HUB Organoid Technology is based on the ground-breaking discovery of Lgr5+ stem cells in the adult intestine by the Hans Clever´s lab¹, which subsequently led to the development of the fist “mini-gut in a dish”². HUB Organoid Technology does not require reprogramming or transformation of stem cells, therefore enabling the development of diseased as well as healthy organoids which preserve the original tissue genetic and epigenetic make up, including clinically-relevant mutations.
Our protocols have been developed, optimized, and standardized for a range of organs and disease types to allow the development of living biobanks of patient-derived organoids that are stable in long-term culture, can be expanded and cryopreserved for multiple applications.
HUB Organoids™ are developed directly from patient material thanks to our exclusive IP-protected technology that allows adult stem cells (ASCs) present in most epithelial tissues to replicate and differentiate in vitro giving rise to functional “mini-organs in a dish”.
HUB Organoids are innovative models derived directly from adult stem cells (ASC) present in all epithelial organs. This is an important distinction which sets HUB Organoids apart from other patient-derived 3D in vitro systems or other organoid technologies using pluripotent stem cells (iPSC) or embryonic stem cell (ESC).
HUB Organoids are: